lenvatinib

This page shows the latest lenvatinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’ multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).

Latest news

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

rights for Lenvima (lenvatinib) and start a series of clinical trials in combination with Keytruda (pembrolizumab).
NICE reverses its rejection of Eisai’s Lenvima

The cost-effectiveness watchdog has now backed the thyroid cancer treatment. The National Institute for Health and Care Excellence (NICE) has recommended the use of Lenvima (lenvatinib) after manufacturer Eisai was ... that NICE is finally recommending
NICE gives green light to Ipsen's Cabometyx

Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s
NICE backs Eisai's Halaven for breast cancer

The company "would like the same opportunity to enable access to our newer cancer drug lenvatinib for radioiodine refractory differentiated thyroid cancer patients, however so far an unacceptable process has again
Eisai wins EU licence for kidney cancer drug Kisplyx

Approved as a second-line combination treatment for advanced RCC. The European Commission has approved Kisplyx (lenvatinib) for the treatment of adults with advanced renal cell carcinoma (RCC) after an accelerated ... We remain committed to exploring the

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Eisai: Bucking the trend with R&D growth

The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director: Competitive Salary Offered

Account Manager- Healthcare Advertising: Negotiable

Account Manager: Negotiable

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Business Director: Competitive Salary Offered

Systematic Reviewer - Oxford: Negotiable

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Associate Medical Director: Excellent PTO, bonus and 401k package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Experienced Medical Writers: Competitive Salary and Benefits

Business Development Director – Health Education: excellent commission

Account Manager / Senior Account Manager: 35, 000-40, 000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Account Manager: Competitive Salary Offered

Account Executive/ Senior Account Executive: competitive Salary Offfered

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Medical (Scientific) Director: £120, 000 benefits

Healthcare Communications Account Directors x 2: Salary TBC

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Account Manager / Account Director: Competative

Subscribe to our email news alerts

PMHub

Add my company

bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...